# Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

> **NCT03541603** · PHASE2 · COMPLETED · sponsor: **Tenax Therapeutics, Inc.** · enrollment: 44 (actual)

## Conditions studied

- Hypertension Pulmonary Secondary
- Heart Failure, Right Sided
- Heart Failure With Normal Ejection Fraction

## Interventions

- **DRUG:** Levosimendan
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT03541603
- **Lead sponsor:** Tenax Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-14
- **Primary completion:** 2020-04-07
- **Final completion:** 2020-04-07
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03541603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03541603, "Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03541603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*